Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

alemtuzumab Injection [Lemtrada]

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Alemtuzumab was designed to reduce the immunogenicity of the parent CD52-specific rat immunoglobulin. Although originally… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
2019
2019
Pneumocystis jirovecii pneumonia (PJP) is a known risk in patients with chronic lymphocytic leukemia treated with alemtuzumab… Expand
2019
2019
La gravedad de los casos identificados ha motivado el inicio de una revisión detallada de la información disponible a nivel… Expand
2019
2019
Tras finalizar la evaluacion europea del balance beneficio-riesgo de alemtuzumab (Lemtrada®) se recomienda restringir la… Expand
2018
2018
Alemtuzumab (Lemtrada®) is a monoclonal antibody recognizing CD52 that selectively depletes T- and B-lymphocytes1 and is… Expand
2018
2018
Alemtuzumab (Lemtrada®) is a humanized monoclonal antibody indicated for the treatment of adult patients with relapsing–remitting… Expand
  • figure 1
Review
2016
Review
2016
Alemtuzumab (Lemtrada™) is a humanized monoclonal antibody approved in more than 50 countries. Within the European Union… Expand
  • table 1
  • table 3
  • table 4
  • table 5
  • table 6
2016
2016
BackgroundAlemtuzumab (Lemtrada®) is a newly approved therapeutic agent for relapsing-remitting multiple sclerosis (RRMS). In… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
2016
2016
Twenty-four approved monoclonal antibodies (mAbs) not indicated for cancer therapy are specific for a total of 20 different… Expand
2015
2015
  • 2015
  • Corpus ID: 58898003
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme, a Sanofi company, today announced posit ive new five-year investigational data from… Expand